Men with advanced prostate cancer undergoing local therapies such as radiation therapy or radical prostatectomy experience significantly more gastrointestinal and sexual issues, along with problems ...

Surgery or radiation for advanced prostate cancer may improve survival but at the cost of treatment-related adverse effects, including gastrointestinal (GI) as well as sexual and urinary conditions, ...

Focal therapy, including HIFU, targets only cancerous prostate areas, preserving organ function and minimizing side effects like erectile dysfunction and urinary incontinence. HIFU is suitable for ...

A 10-year follow up study of nearly 2,500 U.S. men who received prostate cancer treatment will help inform decision making in terms of treatments and side effects for a diverse population. A 10-year ...

A minimally invasive targeted treatment called salvage focal therapy, which targets just the cancerous area of the prostate, can treat men whose prostate cancer has recurred after radiotherapy with ...

Please provide your email address to receive an email when new articles are posted on . Adverse events experienced by men with prostate cancer varied considerably based on the treatment they received, ...

For men with prostate cancer, radical prostatectomy, or surgical removal of the prostate, isn’t guaranteed to be curative, as one expert explained. Among men with prostate cancer, radical ...

For many men with prostate cancer, weeks of daily treatments are no longer the norm. Jonathan Tward, MD, a radiation oncologist at Huntsman Cancer Institute, explains how image guidance, real-time ...

Men treated for prostate cancer after surgery now have clearer evidence that extending hormone therapy from six months to two ...

For men who undergo a radical prostatectomy for the treatment of prostate cancer, post-surgery radiation therapy can play a vital role in reducing the risk of recurrence. Despite its benefits, many ...

Evaluation of the safety and efficacy of daily oral Angelica gigas Nakai (AGN)-INM176 in prostate cancer patients with rising plasma PSA (phase I/II trial). This is an ASCO Meeting Abstract from the ...